Date: 21 August 2012
There is a focus on the negative impact of Article 9 of the draft Deep and Comprehensive Free Trade Agreement (DCFTA), currently being negotiated between the Republic of Moldova and the European Union, on access to medicines in the Republic of Moldova.
The provisions under Art. 9 will allegedly ensure a monopoly by manufacturers of originator drugs and that manufacturers of generic drugs will be unable to enter the market and provide cheaper alternatives to originator drugs for a maximum period of eleven years.
Citation: Anand Grover, 'Communications of the Special Rapporteur on the right to health: Moldova' (2012) OTH 9/2012
© 2024 Human Rights and Drugs.